Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Are you providing the best care for patients with HER2-positive gastrointestinal cancers?

Live Broadcast

1.50 available credits

Information

January 25, 2024

12:00 PM - 01:30 PM EST

Virtual
United States

Details

Presenters

Comments

Overview
Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging live program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program and begin the journey to optimize care for your patients with HER2-gastrointestinal cancers.
Agenda
12:00pm-1:30pm Topics to Include
- HER2 Heterogeneity: Clinical Implications
- Unmet Needs in Second-Line HER2+ G/GEJ Cancers
- Emerging Directions in HER2+ G/GEJ Cancers
- HER2-Amplified Metastatic CRC: Progression Following Frontline Therapy
- The Emerging Role of HER2 in Biliary Tract Cancers
- Treatment-Related Toxicities With HER2-Directed Therapy in GI Cancers
Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO^®, Association for Clinical Oncology, CancerLinQ^®, or Conquer Cancer^® the ASCO Foundation.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Kristen K. Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, TN
Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen,
Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen
Faculty:
James J. Harding, MD
Gastrointestinal Oncologist
Early Drug Development Specialist
Memorial Sloan Kettering Cancer Center
New York, NY
No relevant relationships have been reported at this time.
Filippo Pietrantonio, MD
Medical Oncologist
IRCCS National Cancer Institute
Milan, Italy
No relevant relationships have been reported at this time.
Kanwal P.S. Raghav, MD, MBBS
Associate Professor, Department of Gastrointestinal Medical Oncology
Medical Director, Division of Ambulatory Treatment Centers
The University of Texas MD Anderson Cancer Center
Houston, TX
Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbvie, AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Inc., Sanofi, Seagen
Research: Abbvie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor
Reviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Sara R. Fagerlie, PhD, CHCP, has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- Andrea Mathis has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies
- Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
- Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
- Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
- Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
- Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies
Target Audience
This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Kristen Ciombor, MD

James J. Harding, MD

Filippo Pietrantonio, MD

Kanwal Raghav, MD

Details

Presenters

Comments

Recommended

Overview
Treatment for HER2-positive gastrointestinal malignancies is rapidly evolving. This engaging live program is designed to share practical know-how in the care of patients with gastric/gastroesophageal junction, colorectal, and biliary tract cancers. Topics to be discussed include best practices in HER2 evaluation, current and emerging treatment and sequencing strategies, and mitigation and management of adverse events. Join this expert-led program and begin the journey to optimize care for your patients with HER2-gastrointestinal cancers.
Agenda
12:00pm-1:30pm Topics to Include
- HER2 Heterogeneity: Clinical Implications
- Unmet Needs in Second-Line HER2+ G/GEJ Cancers
- Emerging Directions in HER2+ G/GEJ Cancers
- HER2-Amplified Metastatic CRC: Progression Following Frontline Therapy
- The Emerging Role of HER2 in Biliary Tract Cancers
- Treatment-Related Toxicities With HER2-Directed Therapy in GI Cancers
Not an official event of the 2024 ASCO Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO^®, Association for Clinical Oncology, CancerLinQ^®, or Conquer Cancer^® the ASCO Foundation.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Host:
Kristen K. Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, TN
Dr. Ciombor has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consultant/advisory board: Bayer, Exelixis, Incyte, Merck, Personalis, Pfizer, Replimune, Seagen,
Research grants: Array, BMS, Daiichi Sankyo, Genentech, Incyte, Merck, NuCana, Pfizer/Calithera, Seagen
Faculty:
James J. Harding, MD
Gastrointestinal Oncologist
Early Drug Development Specialist
Memorial Sloan Kettering Cancer Center
New York, NY
No relevant relationships have been reported at this time.
Filippo Pietrantonio, MD
Medical Oncologist
IRCCS National Cancer Institute
Milan, Italy
No relevant relationships have been reported at this time.
Kanwal P.S. Raghav, MD, MBBS
Associate Professor, Department of Gastrointestinal Medical Oncology
Medical Director, Division of Ambulatory Treatment Centers
The University of Texas MD Anderson Cancer Center
Houston, TX
Dr. Raghav has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Abbvie, AstraZeneca, Bayer, Eisai, Daiichi Sankyo, Inc., Sanofi, Seagen
Research: Abbvie, AstraZeneca, Bayer, Guardant Health, HiberCell, Innovent, Janssen, Merck/Serono, Roche/Genentech, Seagen, Xencor
Reviewers/Content Planners/Authors:
- Jorge Bacigalupo has nothing to disclose.
- Cindy Davidson has nothing to disclose.
- Ann Early has nothing to disclose.
- Sara R. Fagerlie, PhD, CHCP, has nothing to disclose.
- Elizabeth Lurwick has nothing to disclose.
- Andrea Mathis has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Integrate a multidisciplinary-based approach with pathologists to optimally implement biomarker testing in patients with gastrointestinal (GI) malignancies
- Improve the identification of patients eligible for HER2-directed therapies in the second-line treatment of advanced HER2-positive gastric/gastroesophageal junction cancer
- Contextualize the evidence from ongoing trials exploring HER2-directed therapy with the potential to impact guidelines and new indications
- Evaluate the clinical significance of HER2 alterations and early clinical trial evidence in patients with biliary tract cancers
- Incorporate therapeutic options to improve response and durability following progression on frontline therapy in HER2-amplified metastatic colorectal cancer
- Develop multidisciplinary care pathways to improve the early recognition and management of treatment-related adverse events with HER2-directed therapies in patients with GI malignancies
Target Audience
This activity is designed to meet the educational needs of medical oncologists, nurse navigators and nurse oncology team members, gastroenterologists, pharmacists, pathologists, and other healthcare professionals who treat patients with GI cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+

Kristen Ciombor, MD

James J. Harding, MD

Filippo Pietrantonio, MD

Kanwal Raghav, MD

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Agenda

Disclosure of Conflicts of Interest

Learning Objectives

Target Audience

Accreditation and Credit Designation Statements

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

System Requirements

Agenda

Disclosure of Conflicts of Interest

Learning Objectives

Target Audience

Accreditation and Credit Designation Statements

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

System Requirements

Recommended

Program Chapters

Segment Chapters

Playlist:

Recommended

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Mastering HER2 in GI Malignancies: Incorporating a Multidisciplinary Approach to Current and Emerging Management

Recommended

Title

Share on ReachMD

Program Chapters

Segment Chapters

Playlist:

Recommended

Get a Dose of ReachMD in Your Inbox and Practice Smarter Medicine